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Abstract
Introduction:  There  is  a  controversy  concerning  the  terminology  and  deﬁnition  of  rhinitis  in
pregnancy.  Gestational  rhinitis  is  a  relatively  common  condition,  which  has  drawn  increasing
interest in  recent  years  due  to  a  possible  association  with  maternal  obstructive  sleep  apnea
syndrome  (OSAS)  and  unfavorable  fetal  outcomes.
Objective:  To  review  the  current  knowledge  on  gestacional  rhinitis,  and  to  assess  its  evidence.
Methods: Structured  literature  search.
Results:  Gestational  rhinitis  and  rhinitis  ‘‘during  pregnancy’’  are  somewhat  similar  conditions
regarding  their  physiopathology  and  treatment,  but  differ  regarding  deﬁnition  and  prognosis.
Hormonal  changes  have  a  presumed  etiological  role,  but  knowledge  about  the  physiopathology
of gestational  rhinitis  is  still  lacking.  Management  of  rhinitis  during  pregnancy  focuses  on  the
minimal intervention  required  for  symptom  relief.
Conclusion:  As  it  has  a  great  impact  on  maternal  quality  of  life,  both  the  otorhinolaryngologist
and the  obstetrician  must  be  careful  concerning  the  early  diagnosis  and  treatment  of  gestational
rhinitis,  considering  the  safety  of  treatment  measures  and  drugs  and  their  current  level  of
evidence.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved. Please cite this article as: Caparroz FA, Gregorio LL, Bongiovanni G, Izu SC, Kosugi EM. Rhinitis and pregnancy: literature review. Braz J
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Rinite  na  gestac¸ão: revisão  de  literatura
Resumo
Introduc¸ão:  Há  grande  confusão  quanto  à  terminologia  e  deﬁnic¸ão  da  rinite  na  gestac¸ão.
A rinite  gestacional  é  uma  condic¸ão  relativamente  comum  que  vem  ganhando  importância  nos
últimos anos  pela  descoberta  de  sua  associac¸ão  com  a  SAOS  materna  e  possíveis  desfechos
desfavoráveis  ao  feto.  Há  pouca  evidência  na  literatura  nacional  sobre  o  tema.
Objetivo:  Revisar  o  conhecimento  cientíﬁco  atual  sobre  a  rinite  na  gestac¸ão  e  suas  evidências
disponíveis.
Método: Revisão  de  literatura  estruturada.
Resultados:  A  rinite  gestacional  e  a  rinite  ‘‘durante  a  gestac¸ão’’  são  condic¸ões  com  alguns  pon-
tos de  ﬁsiopatologia  e  tratamento  semelhantes,  mas  com  deﬁnic¸ões  e  prognósticos  diferentes.
O papel  dos  hormônios  nessas  condic¸ões  vem  sendo  sugerido  por  muitos  trabalhos,  mas  o  con-
hecimento sobre  a  ﬁsiopatogenia  da  rinite  gestacional  ainda  é  escasso.  O  manejo  da  rinite  na
gestac¸ão requer  o  mínimo  de  intervenc¸ão  com  o  maior  alívio  sintomático  possível.
Conclusão:  Dado  o  grande  impacto  na  qualidade  de  vida  da  gestante,  tanto  o  otorrinolaringol-
ogista quanto  o  obstetra  devem  estar  atentos  para  o  diagnóstico  precoce  e  manejo  desta
entidade, considerando  o  perﬁl  de  seguranc¸a e  o  nível  de  evidência  das  medidas  e  medicamentos
disponíveis  atualmente.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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tis,  showing  a  prevalence  ranging  between  18%  and  30%  (forntroduction
estational  rhinitis  is  a  relatively  common  condition,  but  is
eldom  discussed  in  the  national  literature.  It  has  gained
mportance  in  recent  years,  mainly  due  to  the  discov-
ry  of  its  association  with  snoring  and  obstructive  sleep
pnea  syndrome  (OSAS)  during  pregnancy,  and  indirectly
ith  preeclampsia,  a  leading  cause  of  maternal  morbidity
nd  mortality.1 Additionally,  studies  have  shown  its  asso-
iation  with  gestational  hypertension,  intrauterine  growth
etardation,  and  lower  Apgar  scores  in  neonates.1,2
The  ﬁrst  studies  that  associated  the  nasal  obstruction
ymptom  with  female  hormones  appeared  in  the  late  nine-
eenth  century.1 In  1884,  MacKenzie3 presented  a series
f  observations  on  the  increased  volume  of  the  infe-
ior  turbinates  during  menstruation  and  sexual  stimulation,
xpanding  his  theories  to  pregnancy  in  1898.4 However,  it
as  only  in  1943  that  Mohun5 presented  a  series  of  cases
n  this  entity  that  would  be  the  precursor  of  gestational
hinitis,  terming  it  ‘‘vasomotor  rhinitis  of  pregnancy.’’  Nasal
ymptoms  appear  between  the  third  and  seventh  months
f  pregnancy  and  usually  normalize  within  ten  days  after
elivery.5
Gestational  rhinitis  terminology  still  creates  much
onfusion.  Some  authors  emphasize  the  importance  of  dif-
erentiating  rhinitis  ‘‘during  pregnancy’’  from  gestational
hinitis  (or  pregnancy-induced  rhinitis).  Rhinitis  during  preg-
ancy  is  an  entity  that  includes  all  types  of  rhinitis  (allergic,
rug,  non-allergic,  with  vasomotor  component,  among  oth-
rs),  which  would  be  present  before,  during,  and  after
regnancy  by  deﬁnition.6 Gestational  rhinitis,  in  turn,  is
eﬁned  as  nasal  obstruction  that  is  not  present  before  preg-
ancy,  typically  occurs  in  the  second  or  third  trimesters,
ith  a  duration  equal  to  or  greater  than  six  weeks,
hows  no  allergic  cause  or  upper  airway  infection  signs
a
t
qnd  symptoms  resolve  completely  within  two  weeks  after
elivery.1,7,8
The  aim  of  this  study  was  to  conduct  a literature  review
n  gestational  rhinitis  and  extend  some  concepts  with  a  com-
arative  basis  (such  as  physiopathology  and  treatment)  for
ther  types  of  rhinitis  in  pregnancy.
ethods
 literature  review  was  carried  out  in  the  PubMed,  MEDLINE,
nd  SciELO  databases  using  the  terms  ‘‘rhinitis  and  preg-
ancy’’.  Of  the  506  initially  listed  articles,  two  researchers
ndependently  selected  66  and  59  of  them,  respectively,
sing  as  selection  criteria  articles  that  had  gestational
hinitis  or  other  types  of  rhinitis  during  pregnancy  as  the
ain  topic.  Subsequently,  40  common  articles  were  cho-
en  from  the  two  selections,  including  the  most  relevant
egarding  the  criteria  of  deﬁnition,  diagnosis,  etiology,
tiopathogenesis,  differential  diagnosis,  and  treatment  of
oth  gestational  rhinitis  and  rhinitis  during  pregnancy.  The
istribution  of  articles  found  according  to  topic  is  shown  in
able  1.
ncidence and prevalence
pproximately  20%--40%  of  women  report  rhinitis  symptoms
uring  childhood  or  adolescence,  and  10%--30%  of  these
omen  report  symptom  worsening  during  pregnancy.9 Pop-
lation  studies  with  relatively  small  samples  often  do  not
ifferentiate  gestational  rhinitis  from  other  types  of  rhini-ll  types  of  rhinitis  during  pregnancy).7 The  largest  popula-
ion  study  on  prevalence  was  performed  in  Sweden  through
uestionnaires  and  included  599  patients,  excluding  those
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Table  1  Type  of  articles  found  and  correspondence  in  the
references.
Type  of  article  Number  of
articles
References
Subject  review  5  1,7,11,20,41
Diagnostic  2  9,28
Historical  articles  3  3--5
Prevalence  and
incidence  only
1  10
Physiopathology  and
physiopathogeny
10  8,12--19,26
Treatment 5  6,24,27,35,38
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pOutcome  and  associated
conditions
15 2,21,22,23,25,29,
30--34,36,37,39,40
who  already  had  signs  of  rhinitis  before  pregnancy,  revealing
a  prevalence  of  gestational  rhinitis  of  22%.10
Another  recent  study,  however,  assessed  109  pregnant
women  through  questionnaires  and  anterior  rhinoscopy  and
reached  a  prevalence  of  9%  for  gestational  rhinitis,  which
was  consistent  with  other  studies.11 There  were  no  Brazilian
data  on  gestational  rhinitis  prevalence.  This  prevalence  vari-
ation  is  due  not  only  to  the  difﬁculty  of  having  access  to  and
diagnosing  the  disease  and  the  need  for  a  strict  criterion,  but
also  the  fact  that  rhinitis  and  asthma  may  worsen,  improve,
or  remain  unchanged  throughout  the  course  of  pregnancy,  as
well  as  the  fact  that  they  may  vary  in  terms  of  clinical  pre-
sentation  throughout  the  gestational  weeks  and  according
to  each  patient’s  genetic  susceptibility.9
Etiology and physiopathogeny
Although  many  etiological  factors  have  been  proposed,  the
current  knowledge  about  the  physiopathology  of  gestational
rhinitis  is  still  scarce.7,9 It  is  presupposed  that  the  placen-
tal  trophoblastic  hormone  can  stimulate  hypertrophy  of  the
nasal  mucosa  during  pregnancy.9 Moreover,  estrogen  may
contribute  to  this  effect  by  increasing  histamine  receptors
in  epithelial  cells  and  the  microvasculature.12 Progesterone
may  also  play  a  role  by  optimizing  local  vasodilation  in  the
nose  by  increasing  the  circulating  blood  volume  that  occurs
physiologically  during  pregnancy.13
Nasal  physiology  studies  have  shown  signiﬁcant  alter-
ations  in  anterior  rhinoscopy,  rhinomanometry,  and  speciﬁc
rhinitis  questionnaire  scores  compatible  with  decreased
patency  of  air  passage  through  the  nasal  cavity  during  the
course  of  pregnancy.14 However,  all  these  data  --  includ-
ing  the  role  of  hormones--are  conﬂicting,  as  there  have
been  studies  demonstrating  nasal  obstruction  improvement
during  the  course  of  pregnancy  in  a  signiﬁcant  number  of
patients.15
Regarding  risk  factors  for  the  development  of  gesta-
tional  rhinitis,  smoking  was  the  only  one  identiﬁed  with
signiﬁcant  evidence.7,16 The  same  study  found  that  the  spe-
ciﬁc  IgE  to  house  dust  mites  was  a  predisposing  factor
for  the  development  of  the  disease.16 There  is  no  associa-
tion  between  gestational  rhinitis  and  pre-existing  asthma.8
Also,  no  association  was  observed  with  maternal  age,  ges-
tational  age,  child’s  gender,  and  parity.1,7,17 In  relation  to
a
a
w
r107
he  actual  allergic  rhinitis,  it  was  observed  that  the  electron
icroscopy  ﬁndings  in  pregnant  women  with  nasal  symptoms
ere  identical  to  those  with  allergic  rhinitis.18
Considering  this  and  the  fact  that  a  considerable  propor-
ion  of  patients  with  gestational  rhinitis  have  sensitivity  to
ouse  dust  mites,  it  was  suggested  that  patients  with  gesta-
ional  rhinitis  represent  an  allergic  rhinitis  subgroup,  albeit
ith  spontaneous  resolution  after  birth,  according  to  the
eﬁnition.7 Additionally,  serum  markers  for  allergic  disease
uch  as  soluble  intercellular  adhesion  molecule-1  (sICAM-1)
re  not  elevated  in  gestational  rhinitis.7
iagnosis and clinical signiﬁcance
estational  rhinitis  is  characterized  by  nasal  obstruction  in
he  last  six  or  more  weeks  of  gestation,  with  complete  res-
lution  within  two  weeks  after  delivery.1,7,8 The  diagnosis  is
linical  and  can  be  suspected  only  by  the  worsening  of  nasal
bstruction  symptoms  (which  were  not  present  previously)
n  pregnant  patients,  and  is  not  secondary  to  other  condi-
ions  -- the  differential  diagnosis  includes  sinusitis,  allergic
hinitis,  drug-induced  rhinitis,  acute  or  subacute  upper  air-
ay  infection,  and  pregnancy  granuloma.1,9
It  is  important  to  be  cautious  regarding  the  nasal  obstruc-
ion  criteria  in  pregnant  women,  considering  as  positive  only
 worsening  pattern  or  a  symptom  that  has  signiﬁcant  impact
n  patient  quality  of  life,  as  this  is  an  alteration  that  is  part
f  the  normal  physiology  of  pregnancy.19 In  addition  to  the
bstruction,  patients  with  gestational  rhinitis  often  present
ith  rhinorrhea.1
Allergic  rhinitis  is  usually  an  existing  clinical  picture  that
an  also  occur  during  pregnancy.  Unlike  gestational  rhinitis,
n  which  nasal  obstruction  is  the  main  symptom,  patients
ith  allergic  rhinitis  during  pregnancy  have  rhinorrhea,  pru-
itus,  sneezing,  as  well  as  nasal  congestion.9
The  nasal  obstruction  caused  by  rhinitis  --  either  gesta-
ional  or  not  --  may  be  associated  with  a  worsening  of  the
regnant  woman’s  quality  of  sleep,  in  addition  to  snoring
nd  obstructive  sleep  apnea  (OSA),  although  the  latter  may
e  the  result  of  a  combination  of  factors,  involving  weight
ain  during  pregnancy.20
Oral  breathing  caused  by  nasal  obstruction  worsening
uring  gestational  rhinitis  may  lead  to  a  decrease  in  inhala-
ion  of  nitric  oxide  (NO)  --  produced  mainly  in  the  maxillary
inuses  --  to  the  lung,  which  decreases  vascular  resistance,
n  addition  to  improving  local  oxygenation.1,7 The  reduction
n  pulmonary  NO  inhalation  can  have  a deleterious  effect  on
he  fetus,  leading  to  maternal  hypertension,  intrauterine
rowth  retardation,  preeclampsia,  and  lower  Apgar  scores
f  newborns.1,2 Additionally,  nasal  obstruction,  with  quality
f  sleep  impairment,  can  lead  to  the  abuse  of  topical  nasal
econgestants,  leading  to  an  associated  drug-induced  rhini-
is,  which  does  not  usually  resolve  after  delivery.21 However,
here  is  insufﬁcient  evidence  to  establish  an  association
etween  gestational  rhinitis  and  an  unfavorable  outcome  in
regnancy.7
Some  authors,  when  comparing  birth  weight  between
topic  and  non-atopic  pregnant  women,  suggested  that
topy,  by  favoring  a  Th2  pattern  of  immune  response,
ould  lead  to  better  pregnancy  outcomes.21 However,  these
esults  may  have  a  confounding  factor,  as  atopy  has  a
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Table  2  Non-pharmacological  measures  for  the  treatment
of rhinitis  during  pregnancy.
Measure  Beneﬁt
Educational  Adjuvant,  clariﬁcation  of  doubts,
and  reduced  chance  of  using
harmful  substances7,24,25
Physical  exercise  Nasal  obstruction  improvement26
Nasal  irrigation  with Temporary  symptom  relief7
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Table  3  FDA  drug  classiﬁcation  during  pregnancy.27
Risk  Evidence
Risk  A There  is  no  evidence  of  risk  in
pregnant  women.
Well-controlled  studies  have  showed
no problems  in  the  ﬁrst  trimester  of
pregnancy  and  there  is  no  evidence
of  problems  in  the  second  and  third
trimesters.
Risk B There  are  no  adequate  studies  in
pregnant  women.
Animal  experiments  have  detected
no risks.
Risk  C There  are  no  adequate  studies  in
pregnant  women.
There  were  some  side  effects  on  the
fetus  in  animal  experiments,  but  the
product  beneﬁt  may  justify  the
potential  risk  during  pregnancy.
Risk  D There  is  evidence  of  risk  in  human
fetuses.
Only  to  be  used  if  the  beneﬁt
outweighs  the  potential  risk:
life-threatening  situations,  or  in
cases  of  severe  diseases  for  which
safer  drugs  cannot  be  used,  or  if
these  drugs  are  ineffective.
Risk  X Studies  have  disclosed  abnormalities
in the  fetus  or  evidence  of  risk  to  the
fetus.
The  risks  during  pregnancy  outweigh
the  potential  beneﬁts.  Should  not  be
used  during  pregnancy  under  any
circumstances.
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FDA.27,28 Case--control  studies  have  shown  a  statistically  sig-saline  solution
igher  prevalence  in  higher  socioeconomic  groups,  who  tend
o  have  better  nutritional  care.7,22 In  a  national  study  of
30  pregnant  women,  there  was  no  association  between
epeated  miscarriage  and  atopy.23
reatment
egarding  treatment,  most  of  the  studies  show  a  consen-
us  about  the  importance  of  educational  measures  as  the
rst  choice  and  as  an  adjuvant  measure  for  the  management
f  gestational  rhinitis,  mainly  because  symptoms  resolve
pontaneously  after  delivery.7,24 When  advised  early  in  preg-
ancy,  patients  tend  to  resort  less  to  topical  decongestants
nd  will  have  lower  chances  of  developing  drug-associated
hinitis.25
Physical  exercise  has  a  well-established  effect  on  nasal
bstruction  improvement,26 on  the  pregnant  woman’s
eight  control,  and  on  sleep  pattern  improvement.24 Rais-
ng  the  head  of  the  bed  to  30◦--45◦ may  also  help  in
mproving  nasal  obstruction  during  the  night.  Addition-
lly,  nasal  irrigation  with  saline  solution  provides  good
emporary  symptom  relief,  although  there  are  no  speciﬁc
tudies  for  gestational  rhinitis.7 Table  2  summarizes  non-
harmacological  measures  for  the  control  of  gestational
hinitis  or  rhinitis  during  pregnancy.
In  relation  to  topical  decongestants,  they  can  be  divided
nto  short  acting  --  phenylephrine;  intermediate-acting  --
aphazoline;  and  long-acting  drugs  --  oxymetazoline  and
ylometazoline.  All  these  drugs  are  given  a  ‘‘C’’  classiﬁ-
ation  by  the  Food  and  Drug  Administration  (FDA)27 --  the
omplete  FDA  classiﬁcation  of  drugs  for  use  during  preg-
ancy,  shown  in  Table  3.
A  case--control  study  showed  an  association  between  the
se  of  phenylephrine  during  pregnancy  and  the  occurrence
f  congenital  defects.28 Other  studies,  however,  have  failed
o  replicate  this  result.29--31 These  studies  have  also  failed  to
how  adverse  effects  of  intermediate  and  long-acting  topical
econgestants.
Thus,  limited  evidence  suggests  that  oxymetazoline  may
e  used  occasionally  in  one  or  a  few  episodes  of  more
evere  nasal  obstruction,  which  may  be  interfering  with
he  patient’s  sleep,  always  at  the  lowest  possible  dose
nd  preferably  after  the  ﬁrst  trimester,  and  never  close
o  delivery.28 In  this  sense,  it  has  been  shown  that  after
 single  dose  of  topical  nasal  oxymetazoline,  there  were
o  signiﬁcant  changes  in  either  maternal  blood  pressure  or
eart  rate,  or  changes  in  the  uterine  artery  ﬂow  or  umbilical
essels.32
n
o
oFDA, United States Food and Drug Administration.
However,  in  a  more  recent  study,  with  12,734  cases
nd  7606  controls  conducted  with  children  from  the  United
tates  and  Canada,  an  association  was  suggested  between
he  use  of  topical  nasal  decongestants  in  the  ﬁrst  trimester
nd  hypertrophic  pyloric  stenosis,  as  well  as  the  use  of
opical  oxymetazoline  in  the  second  trimester  with  renal
ollecting  system  abnormalities  in  newborns.33 However,
he  study  did  not  mention  the  amount  and  time  of  use  of
rugs.
Many  authors  recommend  the  use  for  no  more  than
ve,  or  even  three  days  of  topical  nasal  decongestants
ue  to  the  proven  risk  of  drug-induced  rhinitis,  which  does
ot  resolve  after  delivery.7 It  is  noteworthy  that  even
he  nighttime  use  only  of  decongestants  can  lead  to  this
ondition.24
The  most  commonly  used  systemic  decongestant,  pseu-
oephedrine,  has  also  received  a  ‘‘C’’  classiﬁcation  by  theiﬁcant  association  between  the  use  of  pseudoephedrine
r  phenylpropanolamine  during  pregnancy  and  the  risk
f  gastroschisis  in  newborns.34 These  ﬁndings  have  not
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Table  4  Safety  level  of  the  most  commonly  used  drugs  for  the  treatment  of  pregnant  women  with  rhinitis.
FDA
classiﬁcation
Drug  class  Indication  Name  of  substance  Detailed  information
A  and  B
Oral
anti-histaminics
AR  Cetirizine Proven  safety  in  animals  and  humans.40
Chlorpheniramine
Loratadine
Intranasal
corticosteroid
AR Budesonide  Safely  used  in  asthmatic  pregnant  women.35
Not  recommended  in  GR.
C
Oral
anti-histaminics
AR Azelastine
Fexofenadine
Intranasal
corticosteroid
AR Fluticasone Not  recommended  in  GR.24
When  considering  the  risk/beneﬁt  in  AR,  its  use
can be  maintained  if  the  pregnant  woman  was
using  before  pregnancy  with  good  results.38Triamcinolone
Mometasone
Systemic
decongestant
AR and  GR  Pseudoephedrine Possible  risk  of  gastroschisis  in  the  fetus  (ﬁrst
quarter).  Maternal  tachycardia,  anxiety,
tremors,  and  insomnia.7,28
Phenylpropanolamine
Topical
decongestant
RA and  RG  Phenylephrine Association  with  congenital  malformations,
especially  in  the  ﬁrst  trimester.28,33
Limited  evidence  suggests  safety  for  one  or  a
few doses  of  oxymetazoline  after  the  ﬁrst
trimester.27
Naphazoline
Oxymetazoline
Xylometazoline
FDA, United States Food and Drug Administration; AR, allergic rhinitis; GR, gestational rhinitis.
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nbeen  replicated  in  later  reviews.28 A  recent  case--control
study,  however,  found  a  statistically  signiﬁcant  association
between  the  use  of  phenylephrine  in  the  ﬁrst  trimester
and  endocardial  wall  closure  defects,  as  well  as  between
the  use  of  phenylpropanolamine  in  the  ﬁrst  trimester
and  external  ear  malformations  and  hypertrophic  pyloric
stenosis.33
Recommendations  for  the  use  of  systemic  decongestants
during  pregnancy  vary  between  different  countries.  Given
the  lack  of  evidence  to  date  and  the  side  effects  of  sys-
temic  decongestants,  which  include  tachycardia,  anxiety,
tremors,  and  insomnia  in  pregnant  women,  they  should
be  especially  avoided  in  the  ﬁrst  trimester  and  their
use  should  be  considered  as  a  risk/beneﬁt  ratio  during
pregnancy.7,28
As  for  topical  corticosteroids,  their  use  is  well  docu-
mented  in  other  types  of  rhinitis  (allergic  or  non-allergic)
during  pregnancy,  but  their  effect  on  gestational  rhini-
tis  speciﬁcally  has  not  been  demonstrated  and,  therefore,
is  not  recommended.7,24 Fluticasone  propionate  showed
no  signiﬁcant  effect  in  a  double-blind  placebo-controlled
trial  of  53  women  with  gestational  rhinitis  treated  for
eight  weeks,  when  assessed  by  clinical  scores  of  nasal
complaints,  peak  expiratory  ﬂow,  and  acoustic  rhinome-
try  before  and  after  treatment.35 The  safety  of  inhaled
budesonide,  demonstrated  by  several  studies  in  asthmatic
t
C
o
hregnant  women,  has  strongly  suggested  that  the  intranasal
oute  of  administration  was  also  safe,  attributing  to  that
roduct  category  ‘‘B’’  of  the  FDA  classiﬁcation  for  use  dur-
ng  pregnancy.36,37 However,  given  the  fact  that  none  of
he  topical  corticosteroids  appear  to  have  adverse  systemic
ffects  at  their  therapeutic  doses,36 the  American  College  of
llergy,  Asthma,  and  Immunology  (ACAAI)  even  states  that
t  is  perfectly  plausible  to  continue  with  a  different  topical
orticosteroid,  rather  than  budesonide,  in  a  patient  with
llergic  rhinitis  who  used  the  drug  with  good  results  before
regnancy.38
In  relation  to  systemic  corticosteroids,  there  are  not
nough  studies  to  generate  recommendations  on  the  dif-
erent  types  of  rhinitis  during  pregnancy.7 Their  use  is
onsidered  an  exception  in  these  cases,  for  short  periods,
o  alleviate  decongestant  use.  Their  use  for  longer  periods
f  time  or  at  higher  doses  can  lead  to  adrenal  insufﬁciency,
ow  birth  weight,  and  congenital  malformations,  especially
left  palate.39
Antihistamines,  in  turn,  are  reserved  for  cases  of  allergic
r  non-allergic  eosinophilic  rhinitis.  In  general,  there  are
ot  enough  data  in  the  literature  to  suggest  that  antihis-
28amines  as  a  group  have  a  deleterious  effect  on  pregnancy.
hlorpheniramine,  loratadine,  and  cetirizine  have  been  rec-
mmended,  as  there  have  been  studies  in  animals  and
umans  demonstrating  their  safety.40
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Sodium  cromoglycate  and  topical  ipratropium  bromide,
he  latter  used  when  there  are  severe  complaints  of  rhi-
orrhea,  have  shown  no  teratogenic  effects  and  can  be
afely  used  for  allergic  rhinitis  during  pregnancy.7 The  use
f  anti-leukotrienes  inhibitors  (such  as  montelukast)  for  the
reatment  of  allergic  rhinitis  during  pregnancy  is  not  rec-
mmended,  as  there  are  safer  alternative  drugs.28 Drug
easurements  in  both  gestational  rhinitis  and  rhinitis  during
regnancy  are  summarized  in  Table  4.
Finally,  surgery  --  volume  reduction  of  inferior  turbinates
-  has  a  limited  role  in  rhinitis  during  pregnancy,  reserved  for
he  most  severe  cases,  which  include  pregnant  women  with
SAS  secondary  to  gestational  rhinitis  and  failure  of  contin-
ous  positive  airway  pressure  (CPAP)  or  other  therapeutic
ethods.7
onclusion
oth  gestational  rhinitis  and  the  ‘‘rhinitis  during  pregnancy’’
re  relatively  common  conditions  that  have  gained  impor-
ance  in  recent  years,  not  only  due  to  the  discovery  of
ssociation  with  maternal  OSAS  and  possible  unfavorable
utcomes  to  the  fetus,  but  also  due  to  the  important  impact
n  the  pregnant  woman’s  quality  life.7,41 Both  the  otorhi-
olaryngologist  and  the  obstetrician  should  be  alert  for  an
arly  diagnosis  and  adequate  treatment,  considering  the
afety  proﬁle  and  current  evidence  of  available  measures
nd  medications.
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